What We Do
September 7, 2020
Sapere Bio selected by the NIH to participate and present at the RESI conference to advance commercial development of innovative technologies
August 25-27, 2020
Connect with us at NextGen Dx, promising in-depth insights from diagnostics leaders, regulators and reimbursement experts
August 24, 2020
New data from Smitherman and colleagues at UNC, utilizing Sapere Bio technology, demonstrates the role of p16 in chemotherapy-accelerated aging, frailty and sarcopenia
July 26, 2020
Doubled office space at "Frontier" headquarters in Research Triangle Park, a entrepreneurial biotech hub
February 25, 2020
Multi-site clinical trial of AKI-Sapere commences, supported by NIA Phase 2 SBIR funding
February 24-27, 2020
Updated data presented at leading international conference on acute kidney injury
March 1, 2019
We attended the 15th Annual Biomarkers in Heart Failure and ACS meeting in La Jolla, CA.
February 26-28, 2019
Poster presentation of new data demonstrating AKI-Sapere can stratify patients by risk AKI before either CABG or cath/PCI.
February 13, 2019
"Life science startup Sapere Bio uses biomarkers to gauge patient health"
January 1, 2019
Sapere derives from the Latin meaning "to know."
November 30, 2018
Natalia Mitin (HealthSpan Dx CEO), Hyman Muss, Andrew Smitherman, and Kirsten Nyrop (UNC clinicians) presented on p16 biomarker applications in oncology. More info
HealthSpan Dx received a multi-year SBIR (Small Business Innovation Research) grant from the NIH and National Institute on Aging (NIA)
September 23-34, 2018
Natalia Mitin, HealthSpan Dx CEO, presented "Bringing Biomarkers of Aging Into the Clinic."
October 1, 2018
HealthSpan Dx tripled office and lab space with a move to custom-designed suits in the innovative Frontier campus.
May 17, 2018
Natalia Mitin provided an overview of our work and history for RTP180, a seminar on entrepreneurship.